Relation between yawning behavior and central serotonergic neuronal system in rats

Okuyama, Shigeru; Shimamura, Hiroko; Hashimoto, Shusuke; Aihara, Hironaka

doi:10.1007/bf00166984

Cited by 14 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, although depletion of endogenous 5-HT by p-chlorophenylalanine or the selective lesioning of serotonergic neurons by 5,7-dihydroxytryptamine has been shown to result in an enhancement of D 2 -like agonist-and physostigmineinduced yawning, enhancing serotonergic activity through treatment with the 5-HT precursor 5-hydroxytryptophan has been shown to inhibit D 2 -like agonist-and physostigmine-induced yawning [81,82]. Similar inhibitions of dopaminergic, serotonergic and cholinergic yawning have also been observed with 5-HT 1A receptor agonists, such as 8-OH-DPAT, S 14506, and S 20499 [80,83].…”

Section: Serotoninmentioning

confidence: 99%

Neurophamacology of Yawning

Collins¹,

Eguibar²

2010

The Mystery of Yawning in Physiology and Disease

View full text Add to dashboard Cite

Yawning is a common behavioral event that is observed in humans, as well as other mammals, birds and reptiles. In humans, yawning often occurs just before bed and upon waking up, and is also associated with tedious or boring situations. Although the physiologic roles of yawning have yet to be fully elucidated, the past 50 years of research has led to a much greater understanding of the neuropharmacologic regulation of yawning. While many of the early studies concluded that yawning was primarily driven by changes in cholinergic neurotransmission, we now know that numerous neurotransmitters and neurohormones are involved in the mediation of yawning, including acetylcholine, dopamine, glutamate, serotonin, oxytocin, GABA, opioids, adrenergics, nitric oxide, as well as the proopiomelanocortin-derived peptides ACTH and alpha-MSH. Furthermore, antagonist interaction studies have clearly defined at least 3 distinct neural pathways involved in the induction of yawning, as well as the hierarchical order through which these different neurotransmitter systems interact to regulate yawning. The following sections will discuss the state of knowledge for each of the major neurotransmitters and neurohormones involved in the regulation of yawning, their interactions with one another, and their place in the hierarchical organization of yawning.

show abstract

Section: Serotoninmentioning

confidence: 99%

Neurophamacology of Yawning

Collins¹,

Eguibar²

2010

The Mystery of Yawning in Physiology and Disease

View full text Add to dashboard Cite

show abstract

“…This type of symptom has been seen with other 5-HT uptake inhibitors, and is likely to be a class phenomenon (13)(14)(15)(16). Yawning is also typical of this type of compound (17). Taken overall, side effects caused by paroxetine were well tolerated.…”

Section: Discussionmentioning

confidence: 87%

A comparison of paroxetine and placebo in depressed outpatients

Dunbar

Claghorn

Kiev

et al. 1993

Acta Psychiatr Scand

View full text Add to dashboard Cite

To compare the safety and efficacy of paroxetine (n = 167) and placebo (n = 169), data from 4 centres using the same protocol were pooled. A double-blind parallel group design was used, with therapy lasting 6 weeks. Significant differences between paroxetine- and placebo-treated patients were found on the major efficacy outcome variables by week 2 and on all efficacy variables by week 4 of the study. Improvement on the sleep factor of the Hamilton Rating Scale for Depression was found after 7 d. Observer and patient global efficacy ratings were in agreement by week 4. No serious adverse events occurred, and paroxetine had no clinically significant effects on vital signs or laboratory safety data. Side effects were more common on paroxetine and were similar to other serotonin reuptake inhibitors. In general, these were well tolerated and did not lead to dropout. Symptoms of increased arousal were not seen during early therapy.

show abstract

“…interfere with yawning. The second is pharmacological antagonism, in that serotonergic stimulation (which appears to result from senktide administration) attenuates the yawning induced by low doses of dopamine agonists and cholinergic agents (Okuyama et al 1987).…”

Section: Resultsmentioning

confidence: 99%

The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation

1988

View full text Add to dashboard Cite

The selective NK-3 tachykinin receptor agonist senktide elicited yawning, chewing mouth movements and sexual arousal following subcutaneous administration (0.1-1.0 mg/kg) in the rat. These responses were not significantly affected by the dopamine antagonist haloperidol (0.03 mg/kg) or by 6-hydroxydopamine lesions of the nigrostriatal projection. In contrast, the behaviours were markedly attenuated by the peripheral and central muscarinic antagonist scopolamine (1 mg/kg), but not by the peripheral muscarinic antagonist N-methylscopolamine (1 mg/kg). These findings suggest that stimulation of NK-3 receptors produces yawning, chewing and sexual arousal by directly activating central cholinergic neurons.

show abstract

Relation between yawning behavior and central serotonergic neuronal system in rats

Cited by 14 publications

References 34 publications

Neurophamacology of Yawning

Neurophamacology of Yawning

A comparison of paroxetine and placebo in depressed outpatients

The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation

Contact Info

Product

Resources

About